Last Updated: November 16, 2026

Claims for Patent: 10,889,587

« Back to Dashboard


Summary for Patent: 10,889,587
Title:Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
Abstract:The disclosure is directed to new crystalline tebipenem pivoxil salt forms, including a crystalline tebipenem pivoxil ethane sulfonate salt form (Form A), a crystalline tebipenem pivoxil ketoglutarate salt form (Form A), tebipenem pivoxil maleate salt forms (Form A and Form B), a tebipenem pivoxil malate salt form (Form A), a tebipenem pivoxil methane sulfonate salt form (Form B), a tebipenem pivoxil hydrobromide salt form (Form B), and a tebipenem pivoxil edisylate salt form (Form A). The disclosure also includes a composition, comprising a crystalline tebipenem pivoxil salt and a pharmaceutically acceptable carrier and further includes a method for treating an antibiotic resistant bacterial infection, comprising administering to a patient in need of such treatment a therapeutically effective amount of a crystalline tebipenem pivoxil salt.
Inventor(s):Akash Jain, Evan Hecker, Richard Edwards, Thierry Bonnaud
Assignee: Spero Therapeutics Inc
Application Number:US16/483,989
Patent Claims: 1. A crystalline tebipenem pivoxil hydrobromide salt form, wherein the XPRD of the form, obtained from a Cu Kα source, has the characteristic 20 values of FIG. 14.

2. A crystalline tebipenem pivoxil hydrobromide salt form characterized by an XPRD diffractogram obtained from a Cu Kα source which comprises peaks at 20 values of 9.3, 13.0, 17.6, 20.8, and 26.8+/−0.2 degrees 2θ; or 10.7, 14.0, 18.7, 20.0, and 23.5+/−0.2 degrees 2θ.

3. A crystalline tebipenem pivoxil hydrobromide salt form of claim 2 characterized by an XPRD diffractogram obtained from a Cu Kα source which comprises peaks at 2θ values of 9.3, 10.7, 13.0, 14.0, 17.6, 18.7, 20.0, 20.8, 23.5, and 26.8.

4. The crystalline tebipenem pivoxil hydrobromide salt form of claim 2, additionally characterized by a DSC profile substantially as shown in FIG. 15.

5. The crystalline tebipenem pivoxil hydrobromide salt form of claim 2 additionally characterized by a DSC profile having an endotherm with an onset of 32.9° C. and a minima at 66.3° C. and a second endotherm with an onset of 186.8° C. and a maxima at 190.8° C.

6. A pharmaceutical composition comprising a tebipenem pivoxil salt and a physiologically acceptable carrier, wherein the tebipenem pivoxil salt comprises at least 90% of the crystalline tebipenem pivoxil hydrobromide salt of claim 2.

7. A dosage form comprising the pharmaceutical composition of claim 6, wherein the dosage form is an intravenous, injectable, topical, or oral dosage form.

8. The dosage form of claim 7, wherein the dosage form in the form of a tablet or capsule.

9. A method for treating a patient infected with a bacterial infection, comprising administering to the patient a therapeutically effective amount of the crystalline tebipenem pivoxil hydrobromide salt form of claim 2.

10. The method according to claim 9, wherein the patient is a human.

11. The method of claim 10, wherein the bacterial infection is a urinary tract infection.

12. The composition of claim 6, wherein the composition contains a second active agent in addition to the crystalline tebipenem pivoxil hydrobromide salt form.

13. The composition of claim 12, wherein the second active agent is an antibiotic.

14. The method of claim 9, wherein a second active agent is administered to the patient in combination the crystalline tebipenem pivoxil hydrobromide salt.

15. The method of claim 14, wherein the second active agent is an antibiotic.

16. The method of claim 6, wherein the bacterial infection is a Gram negative bacterial infection, an E. coli infection, a Klebsiella pneumoniae infection, an Acinetobacter baumannii infection, a Pseudomonas aeruginosa, a Neisseria gonorrhoeae infection, or a Yersinia pestis infection.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.